NVCR · NovoCure Ltd

Track NVCR — free

$15.51 +0.16 (+1.04%) At close · Sep 11

Russell 2000 member Rebalance outlook locked

Market Cap

$1.81B

116.45M

Up next

Next earnings call

Oct 22, 2026 Est · unconfirmed · in 6 wks

Latest filing: 10-Q

filed Jul 23, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$699.19M

Trailing 12 months

Net income (TTM)

−$148.56M

Trailing 12 months

Revenue growth YoY

+15.6%

Year over year

Operating margin

-22.1%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-1.4%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+4.0%

Year over year · more shares

Price change (1Y)

+21.8%

Trailing year

Short interest

9.3%

Latest settlement · 7.6 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Sell Momentum Strong Sentiment Bearish Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.58

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg +7%

above

Price vs 50-day avg −8%

below

RSI (14) 39

neutral

MACD trend Negative

52-week position 55%

mid-range

Momentum

relative strength

Strong

1-month return −11%

trailing

6-month return +31%

trailing

YTD return +20%

this year

Relative strength +13%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $17 › 200d $14 — 50d above 200d

Institutional flow Distributing

-4% holders QoQ · +31 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

9.27% of float · ▲ +17.7% MoM · 7.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

216 holders — near 3-yr low, contrarian setup

Squeeze score 65

elevated · 0–100

Fundamentals

Excellent

Revenue growth +8%

Y/Y

Gross margin 75%

contracting

EPS growth +22%

Y/Y

Free cash flow $-75.7M

Balance sheet $140.5M

net cash

Quant / Vol

risk profile

Very High

Volatility 80%

annualized · 1-yr

Max drawdown −33%

past year

ATR 5.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Jul 23, 2026

Total net revenue · full year 2026 Initiated $710M – $725M

prior FY $655.35M midpoint +9.5% Y/Y

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

2 · 3 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+7% Bullish

Price vs 50-day avg

−8% Bearish

RSI (14)

39 Neutral

MACD trend

Negative Bearish

52-week position

55% Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $17 › 200d $14 — 50d above 200d

Institutional flow Distributing

-4% holders QoQ · +31 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

9.27% of float · ▲ +17.7% MoM · 7.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

216 holders — near 3-yr low, contrarian setup

Price context

position in its 52-week range

Range low $10 Now $16 · 55% Range high $20

vs 200-day avg +7% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
NVCR NovoCure Ltd this stock	$1.81B	+20.0%	+8.3%	—	9.3%
ABT Abbott Laboratories	$177.58B	-18.6%	+5.7%	28.6	1.3%
MDT Medtronic plc	$116.35B	-5.3%	+8.4%	22.4	0.9%
SYK Stryker Corp	$105.70B	-21.6%	+11.2%	28.6	2.0%
BSX Boston Scientific Corp	$62.29B	-54.9%	+12.5%	17.4	3.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

216

% held: 89.7%
Net QoQ: +3.9M sh
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

10.8M

Days to cover: 7.6d
Change: +1.6M sh

View

Short Volume

Short vol %

70%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

366

Value: $6.3K
As of: Aug 11, 2026

View

Off-Exchange

Off-exchange %

42.8%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Buy

Member

Marie Newman

Amount: $15.0K–$50.0K
Traded: Jul 2, 2021

View

Financials

Revenue (FY)

$655.4M

Net income (FY): $-136.2M
EPS diluted: $-1.22

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 9, 2026
This year: 19

View

Proposed Sales

Value

$608.6K

Shares: 39.1K
Filed: Jul 23, 2026

View

Earnings & Events

Earnings Calls

Last call

Jul 23, 2026

View

Performance

	5D	20D	120D	MTD	YTD
NVCR	-12.1%	-10.8%	+31.3%	-12.1%	+20.0%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-10.9%	-9.0%	+13.5%	-11.8%	+7.9%

Key facts CIK 1645113 CUSIP G6674U108 13F (30d) 64 filings 64 filers Visit website Investor relations

NVCR · NovoCure Ltd

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance